Connection

Robert Harrington to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications Robert Harrington has written about Cardiovascular Diseases.
Robert Harrington
Connection Strength
4.312
Cardiovascular Diseases
  1. Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association. Circulation. 2020 03 10; 141(10):e615-e644.
    View in: PubMed
    Score: 0.410
  2. Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being. JAMA. 2012 Nov 07; 308(17):1743-4.
    View in: PubMed
    Score: 0.248
  3. Dueling registries?: an alternative perspective and the case for competitive collaboration. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):486-7.
    View in: PubMed
    Score: 0.226
  4. Platelet inhibitor therapy for patients with cardiovascular disease: looking toward the future. Curr Hematol Rep. 2005 Sep; 4(5):397-404.
    View in: PubMed
    Score: 0.151
  5. Interventional cardiovascular pharmacotherapy: current issues. Am J Cardiovasc Drugs. 2005; 5(2):93-102.
    View in: PubMed
    Score: 0.144
  6. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost. 2004 Dec; 92(6):1182-93.
    View in: PubMed
    Score: 0.143
  7. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes. Semin Thromb Hemost. 2004 Dec; 30(6):639-47.
    View in: PubMed
    Score: 0.143
  8. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30; 146(9):657-672.
    View in: PubMed
    Score: 0.121
  9. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 05 27; 384(21):1981-1990.
    View in: PubMed
    Score: 0.112
  10. 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. J Am Coll Cardiol. 2021 06 22; 77(24):3079-3133.
    View in: PubMed
    Score: 0.112
  11. Taking a stand against air pollution - the impact on cardiovascular disease. Eur Heart J. 2021 Apr 14; 42(15):1460-1463.
    View in: PubMed
    Score: 0.111
  12. Taking a Stand Against Air Pollution-The Impact on Cardiovascular Disease: A Joint Opinion From the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology. Circulation. 2021 Apr 06; 143(14):e800-e804.
    View in: PubMed
    Score: 0.110
  13. Taking a Stand Against Air Pollution-The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology. J Am Coll Cardiol. 2021 04 06; 77(13):1684-1688.
    View in: PubMed
    Score: 0.110
  14. Taking a Stand Against Air Pollution - The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology. Glob Heart. 2021 01 28; 16(1):8.
    View in: PubMed
    Score: 0.110
  15. The Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation. 2020 04 14; 141(15):e743-e745.
    View in: PubMed
    Score: 0.103
  16. Advancing Healthcare Reform: The American Heart Association's 2020 Statement of Principles for Adequate, Accessible, and Affordable Health Care: A Presidential Advisory From the American Heart Association. Circulation. 2020 03 10; 141(10):e601-e614.
    View in: PubMed
    Score: 0.102
  17. Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation. 2019 09 24; 140(13):1115-1124.
    View in: PubMed
    Score: 0.100
  18. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. J Am Coll Cardiol. 2019 09 03; 74(9):1177-1186.
    View in: PubMed
    Score: 0.099
  19. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 08; 7(8):618-628.
    View in: PubMed
    Score: 0.098
  20. Stanford Cardiovascular Institute. Circ Res. 2019 05 10; 124(10):1420-1424.
    View in: PubMed
    Score: 0.097
  21. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary?Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 09 03; 74(9):1167-1176.
    View in: PubMed
    Score: 0.096
  22. Association Between Female Corresponding Authors and Female Co-Authors in Top Contemporary Cardiovascular Medicine Journals. Circulation. 2019 02 19; 139(8):1127-1129.
    View in: PubMed
    Score: 0.096
  23. Heart Centers for Women: Historical Perspective on Formation and Future Strategies to Reduce Cardiovascular Disease. Circulation. 2018 09 11; 138(11):1155-1165.
    View in: PubMed
    Score: 0.093
  24. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).
    View in: PubMed
    Score: 0.086
  25. Disaggregation of Cause-Specific Cardiovascular Disease Mortality Among Hispanic Subgroups. JAMA Cardiol. 2017 03 01; 2(3):240-247.
    View in: PubMed
    Score: 0.084
  26. The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. J Am Coll Cardiol. 2016 10 25; 68(17):1898-1907.
    View in: PubMed
    Score: 0.082
  27. Sharing Data from Cardiovascular Clinical Trials--A Proposal. N Engl J Med. 2016 Aug 04; 375(5):407-9.
    View in: PubMed
    Score: 0.080
  28. Defining a Mobile Health Roadmap for Cardiovascular Health and Disease. J Am Heart Assoc. 2016 07 12; 5(7).
    View in: PubMed
    Score: 0.080
  29. Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015. J Am Heart Assoc. 2015 Nov 05; 4(11).
    View in: PubMed
    Score: 0.076
  30. Clinician Innovator: A Novel Career Path in Academic Medicine A Presidentially Commissioned Article From the American Heart Association. J Am Heart Assoc. 2015 Oct 08; 4(10):e001990.
    View in: PubMed
    Score: 0.076
  31. Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. Am J Med. 2013 Aug; 126(8):723-729.e1.
    View in: PubMed
    Score: 0.065
  32. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.
    View in: PubMed
    Score: 0.056
  33. Towards a new order in cardiovascular medicine: re-engineering through global collaboration. Eur Heart J. 2010 Apr; 31(8):911-7.
    View in: PubMed
    Score: 0.051
  34. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale. Am Heart J. 2008 Apr; 155(4):600-8.
    View in: PubMed
    Score: 0.045
  35. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. J Thorac Cardiovasc Surg. 2007 Jun; 133(6):1604-11.
    View in: PubMed
    Score: 0.043
  36. ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats: the clinical and public health implications for the prevention and control of cardiovascular diseases. Circulation. 2007 Mar 27; 115(12):1656-95.
    View in: PubMed
    Score: 0.042
  37. Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. Health Aff (Millwood). 2007 Jan-Feb; 26(1):62-74.
    View in: PubMed
    Score: 0.041
  38. Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. JAMA Netw Open. 2021 07 01; 4(7):e2117963.
    View in: PubMed
    Score: 0.028
  39. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 04 09; 382(15):1395-1407.
    View in: PubMed
    Score: 0.026
  40. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute?Coronary Syndrome. J Am Coll Cardiol. 2020 01 21; 75(2):133-144.
    View in: PubMed
    Score: 0.026
  41. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019 Sep 28; 394(10204):1169-1180.
    View in: PubMed
    Score: 0.025
  42. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 11 29; 379(22):2097-2107.
    View in: PubMed
    Score: 0.023
  43. Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. Int J Cardiol. 2017 Oct 15; 245:271-276.
    View in: PubMed
    Score: 0.021
  44. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2016 08; 178:176-84.
    View in: PubMed
    Score: 0.020
  45. Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. Am Heart J. 2016 Aug; 178:1-8.
    View in: PubMed
    Score: 0.020
  46. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8.
    View in: PubMed
    Score: 0.020
  47. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012 Jan 05; 366(1):20-33.
    View in: PubMed
    Score: 0.014
  48. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14; 122(11):1056-67.
    View in: PubMed
    Score: 0.013
  49. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. Nephrol Dial Transplant. 2010 Jul; 25(7):2368-75.
    View in: PubMed
    Score: 0.013
  50. Premature release of data from clinical trials of ezetimibe. N Engl J Med. 2009 Aug 13; 361(7):712-7.
    View in: PubMed
    Score: 0.012
  51. Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. Am Heart J. 2007 Apr; 153(4):507-14.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.